PI3K/mTOR Pathway Activation Selected Phase II Study of Everolimus (RAD001) With and Without Temozolomide in the Treatment of Adult Patients With Supratentorial Low-Grade Glioma
Latest Information Update: 02 Jan 2023
At a glance
- Drugs Everolimus (Primary) ; Temozolomide (Primary)
- Indications Astrocytoma; Glioma; Oligodendroglioma
- Focus Therapeutic Use
- 03 Nov 2021 Status changed from active, no longer recruiting to discontinued.
- 06 Jul 2020 Planned primary completion date changed from 31 Jul 2021 to 30 Sep 2021.
- 09 Mar 2020 Planned End Date changed from 1 Jan 2020 to 30 Sep 2021.